Drug Profile
Peceleganan - Jiangsu Protelight Pharmaceutical & Biotechnology
Alternative Names: PL-5Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Jiangsu ProteLight Pharmaceutical and Biotechnology
- Class Anti-infectives; Peptides
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Wound infections
- Phase II Skin and soft tissue infections
Most Recent Events
- 06 Sep 2023 Phase-II clinical trials in Skin and soft tissue infections in USA (Topical) before September 2023 (Jiangsu ProteLight Pharmaceutical and Biotechnology pipeline, September 2023)
- 06 Sep 2023 Preregistration for Wound infections in China (Topical) before September 2023 (Jiangsu ProteLight Pharmaceutical and Biotechnology pipeline, September 2023)
- 15 May 2023 Jiangsu ProteLight Pharmaceutical and Biotechnology initiates enrolment in a phase IIIb trial in Wound infections in China (Topical) (ChiCTR2300071255)